Neon Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Neon Laboratories Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $1.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Neon Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $1.3M Trade | TransData Nexus

Neon Laboratories Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $1.3M Total Trade · DGFT Verified

Neon Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $1.3M across 14 products in 7 therapeutic categories. Based on 136 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Diazepam ($264.4K), Teicoplanin ($215.1K), Fentanyl ($177.4K).

Neon Laboratories Limited — Export Portfolio & Destination Treemap

Neon Laboratories Limited pharmaceutical export portfolio — 14 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Neon Laboratories Limited? — Company Overview & Market Position

Neon Laboratories Limited, established on June 22, 1982, is a public unlisted company headquartered in Mumbai, Maharashtra, India. The company is classified as a non-government entity limited by shares, with an authorized capital of ₹4.00 crore and a paid-up capital of ₹1.27 crore. Over the years, Neon Laboratories has evolved from a small family business into a significant player in the pharmaceutical industry, specializing in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has developed a strong reputation for producing high-quality products, particularly in the anesthesia and oncology segments.

As of the latest available data, Neon Laboratories employs between 501 and 1,000 individuals. The company's registered office is located at 140 Damji Shamji Industrial Complex, Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra 400093, India. Neon Laboratories operates under the Corporate Identification Number (CIN) U24100MH1982PLC027493. The company's official website is neongroup.com, where more information about their products and services can be found.

What Does Neon Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Diazepam$264.4K

Product Portfolio — Top 14 by Export Value

Neon Laboratories Limited exports 14 pharmaceutical products across 7 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Diazepam	CNS & Psychiatric	$264.4K	13	3.5%	7
2	Teicoplanin	Advanced Antibiotics	$215.1K	6	3.4%	5
3	Fentanyl	Analgesics & Antipyretics	$177.4K	8	4.7%	5
4	Ranitidine	Gastrointestinal	$171.4K	13	1.4%	14
5	Morphine	Analgesics & Antipyretics	$146.9K	6	0.8%	8
6	Aminophylline	Respiratory & OTC	$82.0K	9	1.4%	10
7	Vincristine	Oncology	$75.0K	19	3.7%	7
8	Dacarbazine	Advanced Oncology	$63.9K	9	4.5%	6
9	Tamoxifen	Advanced Oncology	$42.0K	25	0.3%	13
10	Mercaptopurine	Advanced Oncology	$40.5K	5	6.9%	2
11	Vinblastine	Oncology	$21.3K	6	2.8%	10
12	Procarbazine	Advanced Oncology	$13.3K	8	5.0%	4
13	Mitoxantrone	Advanced Oncology	$11.2K	3	0.6%	6
14	Daunorubicin	Advanced Oncology	$10.2K	6	1.5%	8

Neon Laboratories Limited exports 14 pharmaceutical products across 7 therapeutic categories with a total export value of $1.3M. The top category is Analgesics & Antipyretics (24.3% of portfolio), followed by CNS & Psychiatric (19.8%), indicating a concentrated portfolio with the top 5 products accounting for 73.1% of total export value.

Neon Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Neon Laboratories Limited operates manufacturing facilities in India, with a focus on producing finished pharmaceutical formulations. The company's manufacturing plant is located at 140 Damji Shamji Industrial Complex, Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra 400093, India. While specific details regarding the plant's capacities and specializations are not publicly disclosed, the company emphasizes innovation and research, particularly in the development of parenteral and oral formulations. Neon Laboratories has also developed a strong reputation in the anesthesia pharmaceutical sector, offering over 40 molecules, including Lidocaine and Bupivacaine, in various dosage forms.

3Key Leadership

Neon Laboratories Limited is led by a team of experienced professionals committed to the company's growth and success. The key executives include:

Ashokkumar Keshrimal Jain: Director since April 1, 2017.

Uttamchand Kesharimal Jain: Director since June 22, 1982.

Pravin Keshrimal Jain: Director since February 6, 1996.

Kishor Champalal Solanki: Director since March 30, 2015.

Abhay Uttamchand Jain: Director since February 5, 2007.

Usha Kishor Jain: Director since March 30, 2015.

These leaders bring a wealth of experience and expertise to the company, guiding its strategic direction and ensuring the delivery of high-quality pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Neon Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Neon Laboratories Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has been actively involved in obtaining necessary regulatory approvals to access these markets. For instance, Neon Laboratories has participated in major pharmaceutical expos and supplies high-quality generic drugs to international markets, primarily targeting B2B partnerships with hospitals, clinics, and distributors. While specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed, the company's participation in international expos and its focus on quality suggest a commitment to meeting the regulatory standards of these markets.

2Emerging Markets

Neon Laboratories Limited has made strategic efforts to penetrate emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's participation in major pharmaceutical expos, such as Arab Health in Dubai (January 27, 2025), CPhI Malaysia in Kuala Lumpur (July 16, 2025), and CPhI Frankfurt in Germany (October 28, 2025), indicates its proactive approach to expanding its global footprint. Additionally, Neon Laboratories has developed a strong reputation in the anesthesia pharmaceutical sector, offering over 40 molecules, including Lidocaine and Bupivacaine, in various dosage forms, which are critical in many healthcare settings. While specific details regarding WHO prequalification and access to these markets are not publicly disclosed, the company's global presence and product offerings suggest a strategic focus on emerging markets.

Neon Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Neon Laboratories Limited has made significant strides in obtaining approvals from the U.S. Food and Drug Administration (FDA). The company has participated in major pharmaceutical expos, such as CPhI Frankfurt in Germany on October 28, 2025, indicating its proactive approach to engaging with international regulatory bodies. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's global presence and participation in international expos suggest a commitment to meeting FDA standards.

2WHO & EU GMP

Neon Laboratories Limited has developed a strong reputation in the anesthesia pharmaceutical sector, offering over 40 molecules, including Lidocaine and Bupivacaine, in various dosage forms. While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certifications are not publicly disclosed, the company's focus on quality and participation in international pharmaceutical expos indicate a commitment to adhering to international manufacturing standards.

3CDSCO & Indian Regulatory

Neon Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Neon Laboratories Limited operates in a competitive landscape, particularly in the anesthesia pharmaceutical sector, where it offers over 40 molecules, including Lidocaine and Bupivacaine, in various dosage forms. While specific market share data is not publicly disclosed, the company's participation in major pharmaceutical expos, such as Arab Health in Dubai (January 27, 2025), CPhI Malaysia in Kuala Lumpur (July 16, 2025), and CPhI Frankfurt in Germany (October 28, 2025), indicates its proactive approach to engaging with international markets and competitors. This engagement suggests that Neon Laboratories is actively positioning itself to compete effectively in the global pharmaceutical market.

2Key Differentiators

Neon Laboratories Limited distinguishes itself through its focus on innovation and research, particularly in the development of parenteral and oral formulations. The company's strong reputation in the anesthesia pharmaceutical sector, offering over 40 molecules, including Lidocaine and Bupivacaine, in various dosage forms, underscores its

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Neon Laboratories Limited

How many pharmaceutical products does Neon Laboratories Limited export from India?

Neon Laboratories Limited exports 14 pharmaceutical products across 7 therapeutic categories. The top exports are Diazepam ($264.4K), Teicoplanin ($215.1K), Fentanyl ($177.4K), Ranitidine ($171.4K), Morphine ($146.9K). Total export value is $1.3M.

What is Neon Laboratories Limited's total pharmaceutical export value?

Neon Laboratories Limited's total pharmaceutical export value is $1.3M, based on 136 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Neon Laboratories Limited cover?

Neon Laboratories Limited exports across 7 therapeutic categories. The largest are Analgesics & Antipyretics (24.3%, 2 products), CNS & Psychiatric (19.8%, 1 products), Advanced Antibiotics (16.1%, 1 products).

Get Full Neon Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.